Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR439859 plus palbociclib versus letrozole plus palbociclib in first-line ER-positive, HER2-negative advanced breast cancer
2020-001824-33Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing SAR439859 plus palbociclib with letrozole plus palbociclib (2 arms). Primary endpoint: Progression-free survival. Started Aug 2020; status: completed.
02
Drugs
amcenestrantpalbociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-001824-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001824-33.